Current perspectives in therapeutic myocardial angiogenesis

Journal of Interventional Cardiology

Volumn 16, Issue 4, 2003, Pages 289-297

  Kinnaird, Tim ^a   Stabile, Eugenio ^a   Epstein, Stephen E ^a   Fuchs, Shmuel ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; VASCULOTROPIN;

ANGINA PECTORIS; ANGIOGENESIS; BIOTECHNOLOGY; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; HEART BLOOD VESSEL; HUMAN; INTRACORONARY INFUSION; ISCHEMIC HEART DISEASE; MEDICAL RESEARCH; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

ANGIOGENESIS INDUCING AGENTS; CORONARY DISEASE; HUMANS; TISSUE THERAPY;

EID: 0041322568     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.08061.x     Document Type: Review

References (58)

1. Risau W. Mechanisms of angiogenesis. Nature 1997;86:671-674.
2. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6(4):389-395.
3. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell specific receptor tyrosine kinases: VEGF's, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13:1055-1066.
4. Dvorak HF, Nagy JA, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999;237:97-132.
5. Schaper W, Ito WD. Molecular mechanisms of coronary collateral vessel growth. Circ Res 1996;79:911-919.
6. Gorge G, Schmidt T, Ito BR, et al. Microvascular and collateral adaptation in swine hearts following progressive coronary artery stenosis. Basic Res Cardiol 1989;84:524-535.
7. Arras M, Ito WD, Scholz D, et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 1998;101:40-50.
8. Banai S, Jaklitsch MT, Shou M, et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994;89:2183-2189.
9. Baffour R, Garb JL, Kaufman J, et al. Angiogenic therapy for the chronically ischemic lower limb in a rabbit model. J Surg Res 2000;93(2):219-29.
10. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994;93(2):662-70.
11. Unger EF, Banai, S, Shou M, et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 1994;35:H1588-H1595.
12. Lazarous DF, Scheinowitz M, Shou M, et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995;91:145-153.
13. Giordano FJ, Ping P, McKirnan D, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996;2:534-539.
14. Epstein SE, Fuchs S, Zhou YF, et al. Therapeutic interventions for enhancing collateral development by administration of growth: Basic principles, early results and potential hazards. Cardiovasc Res 2001;49:532-42.
15. Fuchs S, Baffour R, Zhou YF, et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 2001;37:1726-1732.
16. Crosby JR, Kaminski WE, Schatteman G, et al. Endothelial cells of hemopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 2000;87:728-730.
17. Takahashi T, Kalka C, Masuda H, et al. Ischemia and cytokine induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5:434-438.
18. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-967.
19. Simons M, Bonow RO, Chronos NA, et al. Clinical trial in coronary angiogenesis: Issues, problems, consensus. An expert panel summary. Circulation 2000;102:e73-e86.
20. Pecher P, Schumacher B. Angiogenesis in ischemic human myocardium: Clinical results after 3 years. Ann Thorac Surg 2000;61:1414-1419.
21. Laham RJ, Sellke F, Edelman ER, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999;100:1865-1871.
22. Henry TD, Annex BH, Azrin MA, et al. Final results of the VIVA trial of rhVEGF human therapeutic angiogenesis (abstract). Circulation 1999;100:I-476.
23. Simons M, Annex BH, Laham R, et al. Pharmacological treatment of coronary artery disease with recombinant FGF-2. Circulation 2002;105:788-793.
24. Laham RJ, Chronos NA, Leimbach, et al. Results of a Phase I, open label dose escalation study of intracoronary and intravenous basic fibroblast growth factor in patients with severe ischemic heart disease: 6 months follow-up (abstract). J Am Coll Cardiol 2000;35(Suppl A):73A.
25. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) Trial in Patients with Stable Angina Pectoris. Circulation 2002;105:1291-1297.
26. Unger EF, Goncalves L, Epstein, SE, et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 2000;85:1414-1419.
27. Henry TD, Rocha-Singh K, Isner JM, et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 2001;142(5):872-880.
28. Udelson JE, Dilsizian V, Laham R, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000;102:1605-1610.
29. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100:468-474.
30. Symes JF, Losordo DW, Vale PR et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999;68:830-836.
31. Vale PR, Losordo DW, Milliken CE, et al. Long-term (>2yrs) results of a phase I/II clinical trial if direct myocardial gene transfer of phVEGF165 demonstrate sustained safety and efficacy in patients with end-stage coronary disease (abstract). Circulation 2001;104:II-361.
32. Reilly JP, Grise MA, Delaria GA, et al. Long term (>1year) clinical events following intramyocardial gene transfer of VEGF-2 (abstract). Circulation 2001;104:II-262.
33. Vale P, Losordo DW, Milliken CE, et al. Randomized, single blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001;103:2138-2148.
34. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-2018.
35. Stature C, Westphal B, Kleine HD, et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003;361:45-46.
36. Fuchs S, Satler LF, Kornowski R, et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease - A feasibility study. J Am Coll Cardiol 2003 (in press).
37. Tse HF, Kwong YL, Chan JKF, et al. Angiogenesis in ischemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003;361:47-49.
38. Strauer B, Brehmn M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002;106:1913-1918.
39. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002;106:3009-3017.
40. Seiler C, Pohl T, Wustmann K, et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease. Circulation 2001;104:2012-2017.
41. Epstein SE, Kornowski R, Fuchs S, et al. Angiogenesis therapy: Amidst the hype, the neglected potential for serious side effects. Circulation 2001;104:115-119.
42. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000;156:697-707.
43. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular permeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
44. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-463.
45. Nabel EG, Yang ZY, Plautz G, et al. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis arteries in vivo. Nature 1993;362:844-846.
46. Barger AC, Beeuwkes RD, Lainey LL, et al. Hypothesis: Vasa vasorum and neovascularization of human coronary arteries: A possible role in the pathophysiology of atherosclerosis. N Eng J Med 1984;310:175-177.
47. Herold-Mende C, Steiner HH, Andl T, et al. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest 1999;79:1573-1582.
48. Hanahan D, Folkman J. Patterns and emerging mechanisms of angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
49. Banai S, Jaklitsch MT, Casscells W, et al. Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circ Res 1991;69:76-85.
50. Ku DD, Zaleski JK, Liu S, et al. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993;265:H586-H592.
51. Hariawala MD, Horowitz JR, Esakof D, et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996;63:77-82.
52. Semeza GL. Surviving ischemia: Adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 2000;106:809-812.
53. Wiesner MS, Turley H, Allen WE, et al. Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1α. Blood 1998;7:2260-2268.
54. Vincent KA, Shyu KG, Luo Y, et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1α/VP16 hybrid transcription factor. Circulation 2000;102:2255-2261.
55. Iwaguro H, Tkebuchava T, Vale PR, et al. Direct in vivo gene transfer of HIF-1α/VP16 to ischemic porcine myocardium (abstract). Circulation 2000;102:II-10.
56. Rivard A, Fabre JE, Silver M, Chen D, et al. Age-dependent impairment of angiogenesis. Circulation 1999;99:111-120.
57. Rivard A, Berthou-Soulie L, Principe N, et al. Age-dependant defect in vascular endothelial growth factor expression is associated with reduced hypoxia inducible factor-1 activity. J Biol Chem 2000;38:29643-29647.
58. Abaci A, Oguzhan A, Kahraman S, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999;99:2239-2242.